Trial results

The Effect of Lixisenatide on the Effect of Pituitary Hormones

NCT05804513 on ClinicalTrials.gov · last registry update 2023-06-12

A small phase 4 — 10 participants, against a typical 72. The sponsor logged completion for 31 October 2023. Primary outcome, as filed: Growth hormone area under the curve. lixisenatide is approved in the US, but not for type 1 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it. The registry entry has been edited 1 time since then.

Status

UNKNOWN

Phase

P4

Drug

lixisenatide

Soliqua, Adlyxin

Sponsor

University of Tartu

Sponsor type

Other

Enrollment

10

Started

2023-04-17

Primary completion

2023-10-31 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

Growth hormone area under the curve.

Conditions studied

Healthy · Type 1 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the lixisenatide page for this molecule’s full trial and approval history.